Research To Practice | Oncology Videos

Folgen

• 
  Lung Cancer — Proceedings from a Symposium Held in Conjunction with the American Oncology Network 04.10.2026 50Min.

  Featuring perspectives from Dr Stephen V Liu and Dr Stephen "Fred" Divers, moderated by Dr Divers, including the following topics: Introduction (0:00) EGFR Mutations (2:23) HER2 Alterations (22:40) Available and Investigational Immunotherapies (32:14) Small Cell Lung Cancer (40:48) CME information and select publications
• 
  Prostate Cancer with PTEN Deficiency — An Interview with Dr Neeraj Agarwal 03.10.2026 52Min.

  Featuring an interview with Dr Neeraj Agarwal, including the following topics: Impact of PTEN deficiency on PI3K/AKT/mTOR pathway; optimal approaches to testing (0:00) Approaches to monitoring for disease progression in patients who are PTEN deficient; prognostic significance and implications for testing (7:13) Potential usage of capivasertib as second-line therapy for metastatic androgen pathway modulation-naïve/-sensitive (APMN/S) prostate cancer (15:15) Managing treatment-related adverse events from capivasertib (20:08) Case: A man in his late 50s diagnosed with metastatic APMS prostate cancer and a PTEN deficiency who receives capivasertib (29:17) Case: A man in his late 70s diagnosed with high-volume metastatic APMN prostate cancer and a PTEN deficiency who experiences disease progression on androgen deprivation therapy and enzalutamide (40:39) CME information and select publications
• 
  Prostate Cancer with PTEN Deficiency — An Interview with Dr Neeraj Agarwal (Companion Faculty Lecture) 02.10.2026 23Min.

  Featuring a slide presentation and related discussion from Dr Neeraj Agarwal, including the following topics: Therapeutic targets of systemic therapy in prostate cancer (0:00) Prevalence of genomic alterations in prostate cancer including PTEN deficiency; prognostic and predictive value (3:52) Optimal timing of and approach to PTEN assessment; pathophysiology surrounding PTEN loss (9:29) Comparison of ipatasertib and capivasertib; key findings from Phase III IPATential150 and CAPItello-281 studies (14:26) Safety and tolerability profile of capivasertib; strategies for management of adverse events (19:21) CME information and select publications
• 
  Diffuse Large B-Cell Lymphoma — Proceedings from a Symposium Held in Conjunction with the American Oncology Network 02.10.2026 50Min.

  Featuring perspectives from Dr Ann LaCasce and Dr Stephen "Fred" Divers, moderated by Dr Divers, including the following topics: Introduction (0:00) First-Line Treatment (1:33) Bispecific Antibodies and Chimeric Antigen Receptor T-Cell Therapy (20:36) CME information and select publications
• 
  HER2-Positive Gynecologic Cancers — Microlearning Activity 2: Proceedings from an Independent Satellite Symposium during the SGO Annual Meeting on Women's Cancer 01.10.2026 23Min.

  Featuring perspectives from Dr Joyce F Liu, Dr David M O'Malley and Dr Brian M Slomovitz, moderated by Dr O'Malley, including the following topics: Case: A woman in her mid 60s with metastatic serous endometrial carcinoma that is HER2 IHC 3+ who received first-line carboplatin/paclitaxel/trastuzumab and second-line trastuzumab deruxtecan — Ursula Matulonis, MD (0:00) Commentary: Role of HER2-directed therapy in the maintenance setting for patients with HER2-positive disease — Professor Jonathan A Ledermann (12:29) CME information and select publications
• 
  Ovarian and Endometrial Cancer — Proceedings from a Symposium Held in Conjunction with the American Oncology Network 30.09.2026 51Min.

  Featuring perspectives from Dr Shannon N Westin and Dr Stephen "Fred" Divers, moderated by Dr Divers, including the following topics: Introduction (0:00) Ovarian Cancer (2:22) Endometrial Cancer (37:48) CME information and select publications
• 
  For Oncology Nurses: Non-Small Cell Lung Cancer with a ROS1 Fusion — An Interview with Dr Alexander E Drilon 30.09.2026 58Min.

  Featuring an interview with Dr Alexander E Drilon, including the following topics: Overview of targetable biomarkers in lung cancer (0:00) Biomarker testing for genomic alterations in lung cancer (5:24) Overview of ROS1 alterations in lung cancer (13:44) Efficacy data with ROS1 inhibitors for lung cancer (17:02) Safety data with ROS1 inhibitors for lung cancer (21:15) Case: A woman in her early 50s with a history of non-small cell lung cancer (NSCLC) undergoes biomarker testing to reveal a ROS1 fusion (28:56) Case: A man in his late teens diagnosed with de novo advanced NSCLC with a ROS1 alteration achieves a dramatic response to therapy (46:16) Case: A woman in her early 60s with a history of ROS1-altered NSCLC receives several ROS1 inhibitors (50:52) NCPD information and select publications
• 
  Glucocorticoid Receptor Antagonists for Ovarian Cancer — An Interview with Professor Nicoletta Colombo 29.09.2026 48Min.

  Featuring an interview with Professor Nicoletta Colombo, including the following topics: Mechanistic effects and rationale underlying the use of relacorilant/nab paclitaxel (0:00) Rationale underlying the study design of the Phase II BELLA trial and avenues for future exploration (8:31) Definition of platinum ineligibility; importance of platinum-containing chemotherapy for patients with ovarian cancer (14:02) Findings from a Phase II trial and the subsequent confirmatory Phase III ROSELLA study (20:25) Phase III ROSELLA study: Subgroup analyses, patient-reported outcomes, insights into overall survival data and common adverse events (29:43) Considerations for therapeutic selection and sequencing of novel therapies; ongoing and future investigations (38:46) CME information and select publications
• 
  Glucocorticoid Receptor Antagonists for Ovarian Cancer — An Interview with Professor Nicoletta Colombo (Companion Faculty Lecture) 29.09.2026 36Min.

  Featuring a slide presentation and related discussion from Professor Nicoletta Colombo, including the following topics: Rationale for targeting the glucocorticoid receptor; relacorilant mechanism of action (0:00) Key efficacy and safety findings from a Phase II study of relacorilant/nab paclitaxel for platinum-ineligible ovarian cancer (3:09) Key findings from the Phase III ROSELLA study (7:06) Case: A woman in her early 50s with FIGO Stage IVB platinum-ineligible high-grade serous carcinoma of the fallopian tube enrolls in the Phase III ROSELLA study (15:02) Case: A woman in her late 40s with FIGO Stage IIIB platinum-ineligible high-grade serous ovarian carcinoma enrolls in the Phase II BELLA trial (23:42) CME information and select publications
• 
  Gastroesophageal Cancers — Proceedings from a Symposium Held in Conjunction with the American Oncology Network 28.09.2026 50Min.

  Featuring perspectives from Dr Samuel J Klempner and Dr Stephen "Fred" Divers, moderated by Dr Divers, including the following topics: Introduction (0:00) First-Line Treatment of Metastatic Gastroesophageal Cancer (1:48) Management of HER2-Positive Gastroesophageal Cancer (25:11) Neoadjuvant Therapy for Gastroesophageal Cancer (45:13) Note to listeners: Subsequent to the recording of this symposium, the FDA approved zanidatamab in combination with chemotherapy with and without tislelizumab for HER2-positive gastric, gastroesophageal junction, or esophageal adenocarcinoma based on results from the Phase III HERIZON-GEA-01 trial. CME information and select publications
• 
  Chronic Lymphocytic Leukemia — Proceedings from a Symposium Held in Conjunction with the American Oncology Network 28.09.2026 54Min.

  Featuring perspectives from Dr Farrukh T Awan and Dr Stephen "Fred" Divers, moderated by Dr Divers, including the following topics: Introduction (0:00) First-Line Therapy (2:48) Relapsed/Refractory Disease (39:30) CME information and select publications
• 
  Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia — Reviewing Recent Datasets from the 2026 ASCO Annual Meeting and EHA2026 Congress 25.09.2026 1Std. 28Min.

  Featuring perspectives from Dr Brad S Kahl, Dr Jeff Sharman and Dr Tanya Siddiqi, including the following topics: Introduction (0:00) Trials in Progress (1:12) Chronic Lymphocytic Leukemia (7:09) Diffuse Large B-Cell Lymphoma (32:35) Mantle Cell Lymphoma (58:25) Follicular Lymphoma (1:14:49) CME information and select publications
• 
  HER2-Positive Gynecologic Cancers — Microlearning Activity 1: Proceedings from an Independent Satellite Symposium during the SGO Annual Meeting on Women's Cancer 24.09.2026 9Min.

  Featuring perspectives from Dr Joyce F Liu, Dr David M O'Malley and Dr Brian M Slomovitz, moderated by Dr O'Malley, including the following topic: Case: A woman in her late 50s with a BRCA1 germline mutation and platinum- and PARP inhibitor-resistant metastatic ovarian cancer with low folate receptor alpha level and HER2 IHC 1+ — Professor Jonathan A Ledermann CME information and select publications
• 
  Antibody-Drug Conjugates for Multiple Myeloma — An Interview with Dr Douglas W Sborov (Companion Faculty Lecture) 23.09.2026 23Min.

  Featuring a slide presentation and related discussion from Dr Douglas W Sborov, including the following topics: Overview of the treatment landscape for early relapsed multiple myeloma (MM) (0:00) Belantamab mafodotin (belamaf) mechanism of action and Phase II DREAMM-2 study of belamaf monotherapy in heavily pretreated MM (6:20) DREAMM-7 and DREAMM-8 Phase III trials of belamaf combination strategies in patients with MM in the second- and later-line settings (9:20) Monitoring for and management of belamaf-related ocular toxicities (12:29) Phase I DREAMM-9 trial of belamaf in combination with bortezomib/lenalidomide/dexamethasone (RVd) for transplant-ineligible newly diagnosed MM (16:23) Ongoing trials evaluating alternative belamaf dosing; practical considerations and recommendations for the administration of belamaf (19:07) CME information and select publications
• 
  Antibody-Drug Conjugates for Multiple Myeloma — An Interview with Dr Douglas W Sborov 23.09.2026 49Min.

  Featuring an interview with Dr Douglas W Sborov, including the following topics: DREAMM-2 trial outcomes and clinical development of antibody-drug conjugates for multiple myeloma (MM); mechanism of action of belantamab mafodotin (belamaf) and predictors of response to treatment (0:00) Perspectives on findings from the Phase III DREAMM-7 trial of belamaf combined with bortezomib/dexamethasone for relapsed/refractory MM (4:26) Progression-free survival estimates with current quadruplet induction and maintenance regimens for newly diagnosed MM (6:36) Phase I DREAMM-9 trial and ongoing evaluation of belamaf in the up-front setting (11:48) Potential integration of belamaf into the relapsed/refractory and newly diagnosed MM treatment settings (16:00) Prevention and management of ophthalmic events related to treatment with belamaf (21:27) Case: A man in his mid 60s with multiregimen-recurrent MM receives single-agent belamaf (27:49) Case: A woman in her early 70s with recurrent t(11;14) MM and disease progression on single-agent belamaf experiences a sustained response to talquetamab (33:27) Case: A man in his early 70s with heavily pretreated MM receives belamaf with bortezomib (39:53) CME information and select publications
• 
  Metastatic Triple-Negative Breast Cancer — 5-Minute Journal Club Activity 2 with Dr David W Cescon 22.09.2026 23Min.

  Featuring perspectives from Dr David W Cescon, including the following topics: Clinical treatment of BRCA-mutated metastatic triple-negative breast cancer (0:00) CNS activity of TROP2-directed antibody-drug conjugates (5:36) Autoimmune considerations with immunotherapy (10:09) Treatment of oligoprogressive advanced breast cancer (17:31) CME information and select publications
• 
  Metastatic Triple-Negative Breast Cancer — 5-Minute Journal Club Activity 1 with Dr David W Cescon 21.09.2026 29Min.

  Featuring perspectives from Dr David W Cescon, including the following topics: First-line treatment of metastatic triple-negative breast cancer (mTNBC) in patients not eligible for immunotherapy (0:00) First-line treatment of mTNBC in patients eligible for immunotherapy (12:05) Adverse events (19:39) CME information and select publications
• 
  Gynecologic Cancers — Reviewing Key Presentations from the 2026 ASCO Annual Meeting 17.09.2026 58Min.

  Featuring perspectives from Dr Gottfried E Konecny and Dr Brian M Slomovitz, including the following topics: Introduction (0:00) Preventing Ovarian Cancer (1:04) Endometrial Cancer (5:27) Ovarian Cancer (25:36) Cervical Cancer (54:04) CME information and select publications
• 
  Metastatic Bladder Cancer — Rapid Case Review Issue 8 16.09.2026 25Min.

  Featuring perspectives from Dr Alexandra Drakaki, including the following topics: Case: A man in his late 70s with diabetes and metastatic bladder cancer achieves radiographic response with enfortumab vedotin (EV) and pembrolizumab but develops uncontrolled hyperglycemia (0:00) Case: A man in his early 70s with muscle-invasive bladder cancer receives adjuvant nivolumab and experiences metastatic progression after 9 cycles of therapy (6:23) Case: A woman in her early 70s with Lynch syndrome and metastatic upper tract bladder cancer receives EV/pembrolizumab and develops myasthenia gravis (13:59) Case: A woman in her late 40s with FGFR3 mutant metastatic bladder cancer receives erdafitinib and experiences rising serum phosphate levels (20:04) CME information and select publications
• 
  Metastatic Bladder Cancer — Rapid Case Review Issue 7 16.09.2026 36Min.

  Featuring perspectives from Dr Alexandra Drakaki, including the following topics: Case: A man in his early 80s with bladder cancer and metastatic progression in the viscera and lymph nodes receives enfortumab vedotin (EV) with pembrolizumab — Part 1 (0:00) Case: A man in his early 80s with metastatic bladder cancer achieves a complete response with EV/pembrolizumab therapy but develops gastrointestinal toxicity — Part 2 (5:37) Case: A man in his early 50s with metastatic bladder cancer receives second-line EV monotherapy intermittently (15:09) Case: A woman in her mid 60s with bladder cancer and a history of rheumatoid arthritis develops oligometastatic progression in the lung and receives EV monotherapy (21:03) Case: A man in his mid 80s with HER2-positive (IHC 3+) metastatic bladder cancer receives trastuzumab deruxtecan and develops ground glass opacities in his lungs concerning for pneumonitis (30:43) CME information and select publications